AQST
HEALTHCAREAquestive Therapeutics Inc
AI Insight
What's Moving AQST Today?
No stock-specific AI insight has been generated for AQST yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.93$7.55
$5.03
Fundamentals
Market Cap$592M
P/E Ratio—
EPS$-0.61
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin-137.1%
Debt / Equity—
Trading
Volume3.0M
Avg Volume (10D)—
Shares Outstanding125.5M
AQST News
38 articles- Does US manufacturing give drugmakers a speed edge?Pharmavoice·Jun 23, 2026
- The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New ForecastsYahoo Finance·May 15, 2026
- Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...Yahoo Finance·May 14, 2026
- Aquestive Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 14, 2026
- Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key MetricsYahoo Finance·May 13, 2026
- Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 13, 2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionYahoo Finance·May 13, 2026
- Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 13, 2026
- Aquestive Therapeutics Completes $150 Million Debt Refinancing with OaktreeYahoo Finance·May 12, 2026
- Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 6, 2026
- Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ETYahoo Finance·May 6, 2026
- Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 4, 2026
- Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff RoleGlobeNewswire Inc.·Apr 30, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 27, 2026
- AQST DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQSTGlobeNewswire Inc.·Apr 26, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 23, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQSTGlobeNewswire Inc.·Apr 21, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Eos Energy Enterprises, Inc. Of Class Action Lawsuit and Upcoming Deadlines – EOSEGlobeNewswire Inc.·Apr 21, 2026
- ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQSTGlobeNewswire Inc.·Apr 19, 2026
- AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law FirmGlobeNewswire Inc.·Apr 17, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 16, 2026
- Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff RoleGlobeNewswire Inc.·Apr 13, 2026
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQSTGlobeNewswire Inc.·Apr 10, 2026
- FBRT DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Franklin BSP Realty Trust, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRTGlobeNewswire Inc.·Apr 10, 2026
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarYahoo Finance·Apr 9, 2026
- Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE)GlobeNewswire Inc.·Apr 6, 2026
- AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Stock Dropped Over 37 Percent: Levi & KorsinskyGlobeNewswire Inc.·Apr 6, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 6, 2026
- Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3Yahoo Finance·Mar 31, 2026
- Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual FilmYahoo Finance·Mar 30, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages Franklin BSP Realty Trust, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRTGlobeNewswire Inc.·Mar 29, 2026
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQSTGlobeNewswire Inc.·Mar 29, 2026
- Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. InvestorsGlobeNewswire Inc.·Mar 26, 2026
- Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance OfficerYahoo Finance·Mar 20, 2026
- Aquestive Therapeutics Targets Q3 Anaphylm Resubmission After FDA CRL Flags Human Factors, PK DataMarketbeat·Mar 11, 2026
- Aquestive Therapeutics Targets Q3 Anaphylm FDA Resubmission After CRL, Details Launch Plans at Leerink ConfMarketbeat·Mar 10, 2026
- Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 9, 2026
All 38 articles loaded
Price Data
Open$4.71
Previous Close$4.72
Day High$5.11
Day Low$4.71
52 Week High$7.55
52 Week Low$2.93
52-Week Range
$2.93$7.55
$5.03
Fundamentals
Market Cap$592M
P/E Ratio—
EPS$-0.61
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin-137.1%
Debt / Equity—
Trading
Volume3.0M
Avg Volume (10D)—
Shares Outstanding125.5M
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—